肌层浸润性膀胱癌辅助化疗的增量效用:量化与治疗效果相关的复发风险
该多中心数据库研究纳入950例接受根治性膀胱切除术的cT2-4N0M0肌层浸润性膀胱癌患者,评估辅助化疗对1年无复发生存率的影响。总体未见辅助化疗对1年RFS有影响(p=0.6),但在pT3-4或pN1患者中接受辅助化疗者1年RFS更高(75% vs 54%,p<0.001),且辅助化疗仅对列线图预测1年复发概率>40%的患者带来增量RFS获益。
要点
- 总体未见辅助化疗对1年无复发生存率有影响(p=0.6)。
- pT3-4或pN1患者接受辅助化疗者1年RFS为75% vs 54%(p<0.001)。
- 辅助化疗仅对列线图预测1年复发概率>40%的患者带来增量RFS获益。
核心结论
- 辅助化疗仅对列线图预测1年复发概率>40%的肌层浸润性膀胱癌患者带来增量无复发生存获益,对较低风险疾病未影响癌症复发。
- 作者建议在外部验证前使用可预测复发的列线图进行患者分层。
研究设计与样本
- 多中心数据库研究,纳入950例cT2-4N0M0肌层浸润性膀胱癌患者,接受根治性膀胱切除术,伴或不伴新辅助化疗及辅助化疗。
- 采用Kaplan-Meier分析按辅助化疗使用情况检验1年无复发生存率。
- 将根治性膀胱切除术后列线图导出的1年复发概率按辅助化疗使用情况与实际复发率进行绘图比较。
主要发现
- 总体未见辅助化疗对1年无复发生存率有影响的证据(p=0.6)。
- pT3-4或pN1疾病患者接受辅助化疗者1年无复发生存率更高(75% vs 54%;p<0.001)。
- 在接受过新辅助化疗的患者中,未能证明辅助化疗与无辅助化疗之间存在差异(1年无复发生存率57% vs 76%;p=0.057)。
- 辅助化疗仅对列线图导出的1年复发概率>40%的患者与增量无复发生存获益相关。
临床怎么用
- 作者建议在外部验证前使用可预测复发的列线图对患者进行分层,以识别可能从辅助化疗中获益的患者。
局限性
- 作者建议使用列线图进行患者分层有待外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The availability of new potent systemic therapies for urothelial carcinoma may change the way we use standard chemotherapy perioperatively. In particular, identifying which patients with muscle-invasive bladder cancer (MIBC) would benefit from adjuvant chemotherapy (AC) is compelling. From a multicenter database we selected 950 patients with cT2-4N0M0 MIBC treated with radical cystectomy (RC), with or without neoadjuvant chemotherapy (NAC), and AC. We used Kaplan-Meier analyses to test 1-yr recurrence-free survival (RFS) rates according to AC use. Nomogram-derived probabilities of 1-yr recurrence after RC were plotted against actual recurrence rates according to AC use. Overall, we did not see evidence of an AC effect on the 1-yr RFS rate (p=0.6). Conversely, the 1-yr RFS rate was higher among patients with pT3-4 or pN1 disease who received AC (75% vs 54%; p<0.001). We were unable to demonstrate a difference between AC and no AC among patients who received prior NAC (1-yr RFS 57% vs 76%; p=0.057). As the most important finding, AC was associated with incremental RFS benefits only for patients with a nomogram-derived 1-yr recurrence probability of >40%. Patient summary: Maximizing disease control with adjuvant chemotherapy was beneficial for patients with muscle-invasive bladder cancer who had a calculated recurrence risk of >40% and did not impact cancer recurrence in lower-risk disease. Therefore, patient stratification using the nomogram available for predicting recurrence is advisable pending external validation.
引用
- Pederzoli F, Bandini M, Briganti A, et al. Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. Eur Urol. 2019. PMID: 31303258. doi:10.1016/j.eururo.2019.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。